Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study

We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC). The study included 109 patients with OCCC who did...

Full description

Saved in:
Bibliographic Details
Published inCancer research and treatment Vol. 48; no. 1; pp. 250 - 258
Main Authors Kim, Hee Seung, Choi, Hwa-Young, Lee, Maria, Suh, Dong Hoon, Kim, Kidong, No, Jae Hong, Chung, Hyun Hoon, Kim, Yong Beom, Song, Yong Sang
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Cancer Association 01.01.2016
대한암학회
Subjects
Online AccessGet full text
ISSN1598-2998
2005-9256
DOI10.4143/crt.2014.324

Cover

Abstract We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC). The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes. Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ≥ 46.5, ≥ 11.45, and ≥ 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ≥ 205.4 predicted non-complete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confidence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers. CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC.
AbstractList PURPOSEWe compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC).MATERIALS AND METHODSThe study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes.RESULTSAmong potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ≥ 46.5, ≥ 11.45, and ≥ 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ≥ 205.4 predicted non-complete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confidence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers.CONCLUSIONCA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC.
Purpose We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC). Materials and Methods The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lympho- cyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes. Results Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ! 46.5, ! 11.45, and ! 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ! 205.4 predicted non- complete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confi- dence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers. Conclusion CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC. KCI Citation Count: 0
We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC). The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes. Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ≥ 46.5, ≥ 11.45, and ≥ 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ≥ 205.4 predicted non-complete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confidence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers. CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC.
Author Suh, Dong Hoon
Kim, Kidong
Choi, Hwa-Young
Kim, Yong Beom
Song, Yong Sang
Lee, Maria
Kim, Hee Seung
No, Jae Hong
Chung, Hyun Hoon
Author_xml – sequence: 1
  givenname: Hee Seung
  surname: Kim
  fullname: Kim, Hee Seung
– sequence: 2
  givenname: Hwa-Young
  surname: Choi
  fullname: Choi, Hwa-Young
– sequence: 3
  givenname: Maria
  surname: Lee
  fullname: Lee, Maria
– sequence: 4
  givenname: Dong Hoon
  surname: Suh
  fullname: Suh, Dong Hoon
– sequence: 5
  givenname: Kidong
  surname: Kim
  fullname: Kim, Kidong
– sequence: 6
  givenname: Jae Hong
  surname: No
  fullname: No, Jae Hong
– sequence: 7
  givenname: Hyun Hoon
  surname: Chung
  fullname: Chung, Hyun Hoon
– sequence: 8
  givenname: Yong Beom
  surname: Kim
  fullname: Kim, Yong Beom
– sequence: 9
  givenname: Yong Sang
  surname: Song
  fullname: Song, Yong Sang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25761476$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002074218$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNptkc1vEzEQxS1URNPCjTPykQMb_O2YA1K0oiVSUKU2nC3H66Umu3awnaD89zgN5UucRpr5vXmjeRfgLMTgAHiJ0ZRhRt_aVKYEYTalhD0BE4IQbxTh4gxMMFezhig1OwcXOX9FSDAq8TNwTrgUmEkxAfnukIsbvYWL0A9mHE2J6QBvXd7GkB38ZNLGpQxN6GA7bzDhcOn2bsjQB3izN8mbANvBmQRbNwywNcn6EEfzDs7h6nus3VBcHcb7mAq8K7vu8Bw87c2Q3Yuf9RJ8vvqwaj82y5vrRTtfNpbNaGl6wYxhpqOEHG_tSE-xdERKhTnjayskJb20HAm3tkopLpBlQknDMSKMUHoJXp_2htTrjfU6Gv9Qv0S9SXp-u1powhllvKLvT-h2tx5dZ-vRyQx6m_xo0uFB-Pck-Pu6Zq-ZrA-X7LfXNsVvO5eLHn229SMmuLjLGkuBFKEEi4q--tPrl8ljKBUgJ8CmmHNyvba-mOLj0doPGiN9TF7X5PUxeV2Tr6I3_4ge9_4X_wHPe63x
CitedBy_id crossref_primary_10_1002_jcla_23947
crossref_primary_10_1159_000504450
crossref_primary_10_1186_s13048_020_00693_w
crossref_primary_10_3390_cancers15143607
crossref_primary_10_4143_crt_2016_175
crossref_primary_10_12677_ACM_2023_13112432
crossref_primary_10_2174_1874944502114010162
crossref_primary_10_5604_01_3001_0013_7974
crossref_primary_10_1371_journal_pone_0177520
crossref_primary_10_20473_mog_V31I32023_117_122
crossref_primary_10_18632_oncotarget_20196
crossref_primary_10_3390_ijms222413650
crossref_primary_10_3802_jgo_2017_28_e36
crossref_primary_10_1093_oncolo_oyae325
crossref_primary_10_18231_j_ijogr_2024_004
crossref_primary_10_1155_2017_7943467
crossref_primary_10_1007_s10147_017_1180_4
crossref_primary_10_1016_j_wneu_2020_11_117
crossref_primary_10_3802_jgo_2019_30_e85
crossref_primary_10_5604_01_3001_0054_9810
crossref_primary_10_1016_j_cca_2020_06_034
crossref_primary_10_1186_s13048_019_0544_y
crossref_primary_10_1007_s11523_018_0574_1
crossref_primary_10_1177_1533033818791500
crossref_primary_10_2147_CMAR_S312828
crossref_primary_10_1186_s13048_023_01116_2
crossref_primary_10_1016_j_intimp_2017_02_027
crossref_primary_10_1016_j_smhs_2020_10_001
crossref_primary_10_1007_s00261_025_04842_x
crossref_primary_10_3389_fonc_2022_1023177
crossref_primary_10_4137_BIC_S28378
crossref_primary_10_18632_oncotarget_7216
crossref_primary_10_3233_CBM_160614
crossref_primary_10_3233_CBM_160658
crossref_primary_10_1097_IGC_0000000000001293
crossref_primary_10_1016_j_ygyno_2017_02_026
crossref_primary_10_1007_s00011_017_1026_6
crossref_primary_10_1007_s00404_018_4678_8
crossref_primary_10_3389_fonc_2018_00078
crossref_primary_10_1136_ijgc_2020_001378
crossref_primary_10_1186_s12905_023_02692_7
crossref_primary_10_1002_jcla_22185
crossref_primary_10_5937_jomb0_46035
crossref_primary_10_1186_s13048_023_01106_4
crossref_primary_10_3389_fonc_2024_1360663
crossref_primary_10_1097_MD_0000000000010180
Cites_doi 10.1016/S0301-2115(96)02662-0
10.1164/ajrccm.159.3.9805087
10.1016/S0090-8258(02)00156-7
10.1007/s12094-011-0687-9
10.1016/j.ygyno.2014.01.026
10.1155/2014/349546
10.1093/jnci/dju124
10.1038/bjc.2011.189
10.3802/jgo.2012.23.4.265
10.1002/jso.20494
10.1016/j.ygyno.2013.11.016
10.1186/1479-5876-10-33
10.1097/IGC.0b013e3182070f17
10.1158/1055-9965.EPI-14-0146
10.1002/ijc.27441
10.1016/j.ejogrb.2007.05.012
10.3802/jgo.2014.25.3.236
10.1007/s00262-008-0516-3
10.5468/ogs.2014.57.5.343
10.1161/ATVBAHA.110.207514
10.1016/S0140-6736(00)04046-0
10.1006/gyno.1998.5071
10.1002/cncr.24152
10.2741/3511
ContentType Journal Article
Copyright Copyright © 2016 by the Korean Cancer Association 2016
Copyright_xml – notice: Copyright © 2016 by the Korean Cancer Association 2016
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.4143/crt.2014.324
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-9256
EndPage 258
ExternalDocumentID oai_kci_go_kr_ARTI_254345
PMC4720074
25761476
10_4143_crt_2014_324
Genre Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article
GroupedDBID ---
29B
5-W
53G
8JR
9ZL
AAYXX
ABDBF
ACUHS
ACYCR
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
F5P
HYE
OK1
RPM
TR2
C1A
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
08R
M~E
ID FETCH-LOGICAL-c483t-f64aa4ad3221476d2f317e27791545bc6732f7c506ebc999560c4697a51024233
ISSN 1598-2998
IngestDate Tue Nov 21 21:37:34 EST 2023
Thu Aug 21 14:10:32 EDT 2025
Fri Jul 11 11:34:45 EDT 2025
Thu Apr 03 06:59:24 EDT 2025
Tue Jul 01 03:18:44 EDT 2025
Thu Apr 24 23:01:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Blood platelets
Lymphocytes
Ovarian neoplasms
CA-125 antigen
Clear cell adenocarcinoma
Neutrophils
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c483t-f64aa4ad3221476d2f317e27791545bc6732f7c506ebc999560c4697a51024233
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
G704-000841.2016.48.1.048
http://dx.doi.org/10.4143/crt.2014.324
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC4720074
PMID 25761476
PQID 1760923216
PQPubID 23479
PageCount 9
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_254345
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4720074
proquest_miscellaneous_1760923216
pubmed_primary_25761476
crossref_citationtrail_10_4143_crt_2014_324
crossref_primary_10_4143_crt_2014_324
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-01-01
PublicationDateYYYYMMDD 2016-01-01
PublicationDate_xml – month: 01
  year: 2016
  text: 2016-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Cancer research and treatment
PublicationTitleAlternate Cancer Res Treat
PublicationYear 2016
Publisher Korean Cancer Association
대한암학회
Publisher_xml – name: Korean Cancer Association
– name: 대한암학회
References ref13
ref12
ref15
ref14
ref11
ref10
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref25
ref20
ref22
ref8
ref7
ref9
ref4
ref3
ref6
ref5
Nieswandt (ref21) 1999
24875653 - J Natl Cancer Inst. 2014 Jun;106(6):dju124
21071699 - Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2362-7
22261860 - Int J Cancer. 2012 Jun 15;130(12):2747-60
25264524 - Obstet Gynecol Sci. 2014 Sep;57(5):343-57
19273333 - Front Biosci (Landmark Ed). 2009;14:4044-57
24462730 - Gynecol Oncol. 2014 Mar;132(3):542-50
16550573 - J Surg Oncol. 2006 Apr 1;93(5):379-86
9076425 - Eur J Obstet Gynecol Reprod Biol. 1997 Mar;72(1):73-7
18414853 - Cancer Immunol Immunother. 2009 Jan;58(1):15-23
25050383 - J Immunol Res. 2014;2014:349546
12648592 - Gynecol Oncol. 2003 Mar;88(3):394-9
10096562 - Cancer Res. 1999 Mar 15;59(6):1295-300
9740700 - Gynecol Oncol. 1998 Aug;70(2):255-8
19195045 - Cancer. 2009 Apr 1;115(7):1395-403
24793958 - Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12
22369276 - J Transl Med. 2012;10:33
24333362 - Gynecol Oncol. 2014 Mar;132(3):560-5
25045437 - J Gynecol Oncol. 2014 Jul;25(3):236-48
21775277 - Clin Transl Oncol. 2011 Jul;13(7):499-503
21270624 - Int J Gynecol Cancer. 2011 Feb;21(2):419-23
17644243 - Eur J Obstet Gynecol Reprod Biol. 2008 May;138(1):71-5
21629244 - Br J Cancer. 2011 Jun 28;105(1):93-103
23094130 - J Gynecol Oncol. 2012 Oct;23(4):265-73
10051263 - Am J Respir Crit Care Med. 1999 Mar;159(3):857-63
11229684 - Lancet. 2001 Feb 17;357(9255):539-45
References_xml – ident: ref7
  doi: 10.1016/S0301-2115(96)02662-0
– ident: ref10
  doi: 10.1164/ajrccm.159.3.9805087
– ident: ref17
  doi: 10.1016/S0090-8258(02)00156-7
– ident: ref9
  doi: 10.1007/s12094-011-0687-9
– ident: ref12
  doi: 10.1016/j.ygyno.2014.01.026
– ident: ref8
  doi: 10.1155/2014/349546
– ident: ref24
  doi: 10.1093/jnci/dju124
– ident: ref23
  doi: 10.1038/bjc.2011.189
– ident: ref13
  doi: 10.3802/jgo.2012.23.4.265
– ident: ref5
  doi: 10.1002/jso.20494
– ident: ref19
  doi: 10.1016/j.ygyno.2013.11.016
– start-page: 1295
  volume-title: Lysis of tumor cells by natural killer cells in mice is impeded by platelets
  year: 1999
  ident: ref21
– ident: ref15
  doi: 10.1186/1479-5876-10-33
– ident: ref3
  doi: 10.1097/IGC.0b013e3182070f17
– ident: ref25
  doi: 10.1158/1055-9965.EPI-14-0146
– ident: ref22
  doi: 10.1002/ijc.27441
– ident: ref16
  doi: 10.1016/j.ejogrb.2007.05.012
– ident: ref1
  doi: 10.3802/jgo.2014.25.3.236
– ident: ref14
  doi: 10.1007/s00262-008-0516-3
– ident: ref2
  doi: 10.5468/ogs.2014.57.5.343
– ident: ref20
  doi: 10.1161/ATVBAHA.110.207514
– ident: ref11
  doi: 10.1016/S0140-6736(00)04046-0
– ident: ref18
  doi: 10.1006/gyno.1998.5071
– ident: ref4
  doi: 10.1002/cncr.24152
– ident: ref6
  doi: 10.2741/3511
– reference: 24793958 - Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12
– reference: 12648592 - Gynecol Oncol. 2003 Mar;88(3):394-9
– reference: 24333362 - Gynecol Oncol. 2014 Mar;132(3):560-5
– reference: 22369276 - J Transl Med. 2012;10:33
– reference: 23094130 - J Gynecol Oncol. 2012 Oct;23(4):265-73
– reference: 19195045 - Cancer. 2009 Apr 1;115(7):1395-403
– reference: 25050383 - J Immunol Res. 2014;2014:349546
– reference: 21775277 - Clin Transl Oncol. 2011 Jul;13(7):499-503
– reference: 10051263 - Am J Respir Crit Care Med. 1999 Mar;159(3):857-63
– reference: 17644243 - Eur J Obstet Gynecol Reprod Biol. 2008 May;138(1):71-5
– reference: 21629244 - Br J Cancer. 2011 Jun 28;105(1):93-103
– reference: 25045437 - J Gynecol Oncol. 2014 Jul;25(3):236-48
– reference: 11229684 - Lancet. 2001 Feb 17;357(9255):539-45
– reference: 19273333 - Front Biosci (Landmark Ed). 2009;14:4044-57
– reference: 10096562 - Cancer Res. 1999 Mar 15;59(6):1295-300
– reference: 9740700 - Gynecol Oncol. 1998 Aug;70(2):255-8
– reference: 21071699 - Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2362-7
– reference: 25264524 - Obstet Gynecol Sci. 2014 Sep;57(5):343-57
– reference: 24875653 - J Natl Cancer Inst. 2014 Jun;106(6):dju124
– reference: 16550573 - J Surg Oncol. 2006 Apr 1;93(5):379-86
– reference: 22261860 - Int J Cancer. 2012 Jun 15;130(12):2747-60
– reference: 24462730 - Gynecol Oncol. 2014 Mar;132(3):542-50
– reference: 18414853 - Cancer Immunol Immunother. 2009 Jan;58(1):15-23
– reference: 21270624 - Int J Gynecol Cancer. 2011 Feb;21(2):419-23
– reference: 9076425 - Eur J Obstet Gynecol Reprod Biol. 1997 Mar;72(1):73-7
SSID ssj0064371
Score 2.2563124
Snippet We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels,...
PURPOSEWe compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125)...
Purpose We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125)...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 250
SubjectTerms Adult
Aged
Aged, 80 and over
CA-125 Antigen - metabolism
Cohort Studies
Female
Humans
Inflammation Mediators - blood
Leukocyte Count
Middle Aged
Odds Ratio
Original
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - immunology
Ovarian Neoplasms - metabolism
Prognosis
Retrospective Studies
Survival Analysis
의약학
Title Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study
URI https://www.ncbi.nlm.nih.gov/pubmed/25761476
https://www.proquest.com/docview/1760923216
https://pubmed.ncbi.nlm.nih.gov/PMC4720074
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002074218
Volume 48
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Cancer Research and Treatment, 2016, 48(1), , pp.250-258
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe6TUK8IL4pXzISfqpSmsSJbd6StNVADCTUSXuLUs9h1ViKuhYk_nPeuLOTLqk2afASRc7VcfP7Jb47350JeTtScg4TQeApY3CZUReenBvhBX4pdRgVuizR33H0OT485h9PopNe708rammzng_172vzSv4HVWgDXDFL9h-Q3XYKDXAO-MIREIbjrTB25cYXGt7yEpC9cCvmX13Yq7F5OJifi77xLPFAyRh8whghGwL75SdYyfByZ7hvxCBDF16G-wpVy4vCpavPfi2t89fA5eUZqOk26LCzDJwhZ1aDumKQS5Lbhq43WLJJwlKFIRWTMVNjlmRskjGJjVciGUsjpjIropji2KIkk35bBH6cwpWUJYJJaU_iujsVMcnbspLb7lImp9gj9gvnsu3l8He9HFY8a0bqxmO7xvG4FtdTAmLtz7nCHBO3z_XQ2DZbe1UFUeez7Yrf1hpA4IrJ704uHFRLYIReYQiuz4ehS_7u1vDemVs7VbzP9SL_tszPVznYKh9yLEPAoz1yEAiBEQYHSTpOp40agQuqrthv_Rdc1gYO4l17CB19aq9aldeZSrsRvy0Vanaf3KttH5o4Ij8gPVM9JHeO6uiOR-Sy4TNt85k2fKY1nymwjDo-U8dnuqhozWdq-UyRz3TL5_c0ocBm6thMHZupZfNjcjydzLJDr94UxNNchmuvjHlR8OIUJiKfi_g0KEEDNvAIFRoDcx2LMCiFjkaxmWuFedsjzWMlCph80HYIn5D9almZZ4Se8lJL4ysRKsm1Btt_VAhTFoExYBTIsE8GzaPNdV0xHzdu-Z6D5YxA5ABEjkDkAESfsK30D1cp5ga5N4CSJcONpACZBsMcPve4hldUZrm5zH0Rj8AmC_y4T546TLd3Q98BPpM-ER20twJ4v-6VanFmS8pzgWsW_PktxvaC3L16QV-S_fVqY16BYr6ev64p_BePl9Al
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systemic+Inflammatory+Response+Markers+and+CA-125+Levels+in+Ovarian+Clear+Cell+Carcinoma%3A+A+Two+Center+Cohort+Study&rft.jtitle=Cancer+research+and+treatment&rft.au=%EA%B9%80%ED%9D%AC%EC%8A%B9&rft.au=%EC%B5%9C%ED%99%94%EC%98%81&rft.au=%EC%9D%B4%EB%A7%88%EB%A6%AC%EC%95%84&rft.au=%EC%84%9C%EB%8F%99%ED%9B%88&rft.date=2016-01-01&rft.pub=%EB%8C%80%ED%95%9C%EC%95%94%ED%95%99%ED%9A%8C&rft.issn=1598-2998&rft.eissn=2005-9256&rft.spage=250&rft.epage=258&rft_id=info:doi/10.4143%2Fcrt.2014.324&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_254345
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon